Melanoma antigen peptide and uses thereof

Patent metadata

Field	Value
Publication number	US-9475841-B2
Application number	US-201214402850-A
Country	US
Kind code	B2
Filing date	May 22, 2012
Priority date	May 22, 2012
Publication date	Oct 25, 2016
Grant date	Oct 25, 2016

Abstract

The present invention relates to a melanoma antigen peptide comprising the amino acids sequence selected in the group consisting of SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15 or a function-conservative variant thereof. Moreover the invention also relates to a melanoma antigen peptide according to the invention for use in the prevention or the treatment of melanoma in patient.

First claim

The invention claimed is:

1. A method of treating melanoma in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of and agent selected from the group consisting of
i) a melanoma antigen peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14 and SEQ ID NO:15, wherein said melanoma antigen peptide is an amino acid sequence of less than 40 amino acids long,
ii) a fusion protein comprising the melanoma antigen peptide as defined in point i) and a melanoma antigen peptide comprising the amino acid motif:

TX 7 NDECWPX 9 (SEQ ID NO: 23) wherein X 2 is leucine, methionine, valine, isoleucine or glutamine and X 9 is alanine, valine or leucine, and
iii) a nucleic acid sequence encoding the melanoma antigen peptide as defined in point i) or the fusion peptide as defined in point ii).

2. The method according to claim 1 wherein the patient is genotyped with HLA-DRβ1*1101 or HLA-DRβ1*0101 alleles.

3. The method according to claim 1 , wherein the melanoma antigen peptide comprises the amino acid sequence SEQ ID NO:10.

4. A method of treating melanoma in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of an agent selected from the group consisting of:
i) a melanoma antigen peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 15, wherein said melanoma antigen peptide is an amino acid sequence of less than 30 amino acids long,
ii) a fusion protein comprising the melanoma antigen peptide as defined in point i) and a melanoma antigen peptide comprising the amino acid motif:
TX 2 NDECWPX 9 (SEQ ID NO: 23) wherein X 2 is leucine, methionine, valine, isoleucine or glutamine and X 9 is alanine, valine or leucine, and
iii) a nucleic acid sequence encoding the melanoma antigen peptide as defined in point i) or the fusion protein as defined in point ii).

5. The method according to claim 4 , wherein the melanoma antigen peptide is an amino acid sequence of less than 25 amino acids long.

Assignees

• Labarriere Nathalie
• Lang Francois
• Bobinet Mathilde
• Rogel Anne
• Inserm (Institut Nat De La Sante Et De La Rech Medicale)
• Centre Nat De La Rech Scient (Cnrs)
• Univ D'Angers

Inventors

• Labarriere Nathalie
• Lang Francois
• Bobinet Mathilde
• Rogel Anne

Classifications

• G01N33/5751

  of the skin, e.g. melanoma · CPC title

• C07K7/08 Primary

  having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) · CPC title

• C07K2319/00

  Fusion polypeptide · CPC title

• C07K14/47

  from mammals · CPC title

• C07K16/3053

  Skin, nerves, brain · CPC title